OncoMatch/Clinical Trials/NCT07250750
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Is NCT07250750 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including IM-101 Part A and IM-101 Part B for myasthenia gravis.
Treatment: IM-101 Part A · IM-101 Part B — The goal of this clinical trial is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of IM-101 in adult participants with AChR antibody-positive gMG. Subsequently, the safety and efficacy of the selected IM-101 dose-regimen will be tested in participants with AChR antibody-negative gMG and participants with AChR antibody-positive or AChR antibody-negative oMG.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Excluded: MUSK antibody positive
Prior therapy
Must have received: background therapy for MG
On a stable dose of background therapy for the treatment of MG
Cannot have received: IM-101 (IM-101)
Previous exposure to IM-101
Cannot have received: complement inhibitor
Exception: if failed due to intolerability or lack of efficacy
Has been treated with any complement inhibitor, but failed due to intolerability or lack of efficacy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Neurology of Central Florida Research Center, LLC · Altamonte Springs, Florida
- SFM Clinical Research, LLC · Boca Raton, Florida
- Aqualane Clinical Research · Naples, Florida
- Medsol Clinical Research Center · Port Charlotte, Florida
- University of South Florida · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify